TY - GEN N1 - Polish - Japan Issue N2 - In recent years, the antisense strategy for cancer therapy has progressed from in vitro culturestudies, to investigations in animal models, and now to clinical studies. We describe here thecurrent state of progress toward gene-directed antisense-based cancer therapy targetingBCR/ABL oncogene, primarily from the viewpoint of initial proof-of-concepts studies in animalmodels of human leukemias and phase I clinical investigations. L1 - http://rcin.org.pl/Content/146559/PDF/POZN271_182229_biotechnologia-1996-no4-skorski.pdf M3 - Text J2 - Antisense Oligodeoxynucleotides: from the Bench to the Patient PY - 1996 IS - 4 EP - 115 KW - biotechnology A1 - Skórski, Tomasz A1 - Nieborowska-Skórska, Małgorzata A1 - Szczylik, Cezary A1 - Calabretta, Bruno PB - Committee on Biotechnology PAS PB - Institute of Bioorganic Chemistry PAS VL - 35 SP - 108 T1 - Antisense Oligodeoxynucleotides: from the Bench to the Patient UR - http://rcin.org.pl/dlibra/publication/edition/146559 ER -